KalVista Pharmaceuticals ( (KALV) ) has provided an update.
KalVista Pharmaceuticals announced a $55 million underwritten offering of 5.5 million shares at $10 per share, alongside a $5 million private placement with DRI Healthcare Acquisitions. These transactions aim to fund the clinical development and commercialization of sebetralstat, with remaining proceeds used for general purposes. The offerings are set to close on November 5, 2024, highlighting KalVista’s strategic financial maneuvers to support its growth and drug development initiatives.
For a thorough assessment of KALV stock, go to TipRanks’ Stock Analysis page.
